Future microbiology
-
Future microbiology · Jan 2015
ReviewClinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
The first clinical Phase III trial evaluating a malaria vaccine was completed in December 2013 at 11 sites from seven sub-Saharan African countries. This systematic review assesses data of Phase I-III trials including malaria-naive adults and adults, children and infants from malaria endemic settings in sub-Saharan Africa. ⋯ The RTS,S/AS01 malaria vaccine may become available on the market in the coming year. If so, further strategies should address challenges on how to optimize vaccine efficacy and implementation of RTS,S/AS01 vaccine within the framework of established malaria control measures.
-
Future microbiology · Jan 2015
Antimicrobial activity and resistance selection of different bioglass S53P4 formulations against multidrug resistant strains.
This study aimed to evaluate the antimicrobial activity of two different formulations of bioglass BAG-S53P4 against multiresistant microorganisms involved in bone infections, and the capability of bioglass to select for resistance. ⋯ BAG-S53P4 has a significant potential as bone substitute for the treatment of infections caused by multiresistant microorganisms.
-
Future microbiology · Jan 2015
Distribution of nontuberculous mycobacteria in treated patients with pulmonary disease in Greece - relation to microbiological data.
The aim was to assess the distribution of nontuberculous mycobacteria (NTM) in treated patients with pulmonary disease (PD) in Greece. ⋯ The increasing number of NTM PD in Greece is a consequence of their isolation being more frequently considered as clinically relevant.
-
Future microbiology · Jan 2015
Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
High rates of morbidity and mortality have been linked to the emergence of antimicrobial-resistant Gram-negative pathogens, especially in the hospital setting. Infections due to extended-spectrum-β-lactamase producing Enterobacteriaceae (e.g., Escherichia coli, Klebsiella pneumoniae) and multidrug-resistant Pseudomonas aeruginosa pose a major health threat and dramatically reduce the therapeutic options to achieve an appropriate treatment. ⋯ Phase II and III trials have shown high efficacy and good tolerability in complicated urinary and intra-abdominal infections compared with standard therapy. A study for the treatment of nosocomial pneumonia is planned.